PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2011 | 6 | 5 | 545-549
Article title

Comparison of prostate cancer patient’s survival in Belarus and Lithuania

Content
Title variants
Languages of publication
EN
Abstracts
EN
Publisher

Journal
Year
Volume
6
Issue
5
Pages
545-549
Physical description
Dates
published
1 - 10 - 2011
online
9 - 8 - 2011
Contributors
  • Lithuanian Cancer Registry, Institute of Oncology, Vilnius University, LT-08660, Vilnius, Lithuania, giedre.smailyte@vuoi.lt
author
  • N.N. Alexandrov National Cancer Center of Belarus, 223040, Minsk, Belarus
author
  • N.N. Alexandrov National Cancer Center of Belarus, 223040, Minsk, Belarus
author
  • N.N. Alexandrov National Cancer Center of Belarus, 223040, Minsk, Belarus
  • Lithuanian Cancer Registry, Institute of Oncology, Vilnius University, LT-08660, Vilnius, Lithuania
References
  • [1] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food. Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.200700511[WoS][Crossref]
  • [2] Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581–592. http://dx.doi.org/10.1093/annonc/mdl498[Crossref]
  • [3] Coebergh J.W.W., Sant M., Berrino F., Verdecchia A., Survival of adult cancer patients in Europe diagnosed from 1978–1989: the EUROCARE II study, Eur. J. Cancer, 1998, 34, 2137–2178. http://dx.doi.org/10.1016/S0959-8049(98)99063-3[Crossref]
  • [4] Berrino F., Capocaccia R., Coleman M.P., Estève J., Gatta G., Hakulinen T., et al., Survival of cancer patients in Europe. The EUROCARE-3 study, Annal. Oncol., 2003, 14(suppl 5), v9–155. http://dx.doi.org/10.1093/annonc/mdg750[Crossref]
  • [5] Coleman M.P., Gatta G., Verdecchia A., Estève J., Sant M., Storm H., et al., EUROCARE-3 summary: cancer survival at the end of 20th century, Annal. Oncol., 2003, 14(suppl 5), v128–149. http://dx.doi.org/10.1093/annonc/mdg756[Crossref]
  • [6] Ederer F., Axtell L.M., Cutler S.J., The relative survival rate: a statistical methodology, Natl. Cancer Inst. Monogr., 1961, 6, 101–121 [PubMed]
  • [7] Dickman P., [Accessed 29 June 2009], Available at http://www.pauldickman.com.
  • [8] Sant M, Capocaccia R, Coleman MP, Berrino F., Gatta G., Micheli A., et al., Cancer survival increases in Europe, but international differences remain wide, Eur. J. Cancer, 2001, 37, 1659–1667. http://dx.doi.org/10.1016/S0959-8049(01)00206-4[Crossref]
  • [9] Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., et al., Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data, Lancet Oncol., 2007, 8, 784–796. http://dx.doi.org/10.1016/S1470-2045(07)70246-2
  • [10] Gondos A., Bray F., Brewster D.H., Coebergh J.W., Hakulinen T., Janssen-Heijnen M.L., et al., Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries, Eur. J. Cancer, 2008, 44, 1463–1475. http://dx.doi.org/10.1016/j.ejca.2008.03.010[Crossref]
  • [11] Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., et al., Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival, Cancer, 2004, 101, 3–27. http://dx.doi.org/10.1002/cncr.20288[Crossref]
  • [12] Verdecchia A., Guzzinati S., Francisci S., De Angelis R., Bray F., Allemani C., et al., Survival trends in European cancer patients diagnosed from 1988 to 1999, Eur. J. Cancer, 2009, 45, 1042–1066. http://dx.doi.org/10.1016/j.ejca.2008.11.029[Crossref]
  • [13] Brenner H., Arndt V., Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis, J. Clin. Oncol., 2005, 23, 441–447. http://dx.doi.org/10.1200/JCO.2005.11.148[Crossref]
  • [14] Gondos A., Bray F., Hakulinen T., Brenner H., Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis, Ann. Oncol., 2009, 20, 564–573. http://dx.doi.org/10.1093/annonc/mdn639[Crossref][WoS]
  • [15] D’Ambrosio G., Samani F., Cancian M., De Mola C., Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database, Eur. J. Cancer Prev., 2004, 13, 383–386. http://dx.doi.org/10.1097/00008469-200410000-00005[Crossref]
  • [16] Etzioni R., Penson D.F., Legler J.M., Overdiagnosis due to prostate specific antigen screening: lessons from U.S. prostate cancer incidence trends, J. Natl. Cancer Inst., 2002, 94, 981–990. [Crossref]
  • [17] Gavin A., McCarron P., Middleton R.J., Savage G., Catney D., O’Reilly D., et al., Evidence of prostate cancer screening in a UK region, BJU Int., 2004, 93, 730–734. http://dx.doi.org/10.1111/j.1464-410X.2003.04716.x[Crossref]
  • [18] Kumar S., Shelley M., Harrison C., Coles B., Wilt T.J., Mason M.D., Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst. Rev., [2006CD006019].
  • [19] Mike S., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D., Chemotherapy for hormone-refractory prostate cancer, Cochrane Database Syst. Rev., [2006CD005247].
  • [20] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.200700511[WoS][Crossref]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-011-0058-5
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.